Xellia Pharmaceuticals has acquired Fresenius Kabi's lyophilized vial manufacturing facility in Raleigh, North Carolina. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA. Financial details are not disclosed.

The manufacturing site is located close to Research Triangle Park and is Xellia's first facility in the US and significantly expands the company's manufacturing capacity for injectable pharmaceutical products. Xellia intends to retain all of the approximately 80 staff currently employed at the site and will continue to manufacture certain products at the site for Fresenius Kabi. In the future, Xellia plans to employ more staff as it expands the site further.

Commenting on the acquisition, CEO Xellia Carl-Ã…ke Carlsson said: “This is a great opportunity for us to expand our manufacturing capabilities into the US, which is a key market for us. We have great respect for Fresenius Kabi and its employees and have been in partnership with the company for years as a preferred, trusted supplier of active pharmaceutical ingredients. I believe this acquisition will be a win-win situation, benefiting both companies and our customers.”

Xellia said in it is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients to better serve its global customer base of over 500 pharmaceutical companies by supplying the finished dosage form of its drugs. This acquisition is part of the latest phase of Xellia's on-going global expansion plans, which include an investment of $2.0 million at the company's Product and Innovation R&D Center of Excellence in Zagreb, Croatia in May 2014.  

Source: Xelia Pharmaceuticals